CMC Regulatory Landmarks: Tracing the Evolution of Current Practices
CMC Regulatory Landmarks: Tracing the Evolution of Current Practices

CMC Regulatory Landmarks: Tracing the Evolution of Current Practices

A historical perspective on major regulatory milestones and how they have shaped current CMC practices.

Watch the YouTube Video Here!

Explore the pivotal moments in the history of Chemistry, Manufacturing, and Controls (CMC) regulations with our comprehensive guide, 'CMC Regulatory Landmarks.' This insightful resource delves into the major regulatory milestones that have significantly influenced today's CMC practices. From the inception of critical guidelines to the evolution of compliance standards, our guide offers a detailed historical perspective, illuminating how past developments have shaped current methodologies and strategies in the pharmaceutical and biologics sectors.


Creating a historical perspective on major regulatory milestones in CMC (Chemistry, Manufacturing, and Controls) is crucial for understanding how current practices have been shaped. Here are seven landmark acts, regulations, and major guidances that have significantly influenced CMC regulatory landscape:

  • Federal Food, Drug, and Cosmetic Act (1938)
  • Kefauver-Harris Amendment (1962)
  • Current Good Manufacturing Practice (cGMP) Regulations:
  • International Conference on Harmonisation (ICH) Guidelines (1990s-present)
  • FDA’s Process Analytical Technology (PAT) Initiative (2004)
  • Quality by Design (QbD) Principles (2000s)
  • FDA Safety and Innovation Act (FDASIA) (2012)
  • FDA’s Guidance on Quality Considerations for Continuous Manufacturing (2021)
  • ICH Q12

Each of these milestones has contributed to the evolution of CMC regulatory practices, emphasizing safety, efficacy, quality, and manufacturing consistency in pharmaceutical development. Understanding these historical developments is crucial for companies like Enkrisi in navigating the current regulatory landscape and advising clients effectively.

These developments reflect the ongoing evolution of the regulatory environment, emphasizing efficiency, innovation, and lifecycle management in pharmaceutical manufacturing and quality control. For a company like Enkrisi, staying abreast of such developments is crucial for providing informed and up-to-date regulatory strategy and compliance advice to clients.


Ideal for regulatory professionals, quality assurance specialists, and pharmaceutical companies, this guide is an invaluable tool for understanding the complexities and nuances of CMC regulatory frameworks. Stay informed and ahead in your field with our expert analysis and strategic insights into the ever-evolving world of CMC regulations."


Introducing?Enkrisi?– the leading Regulatory CMC consulting group helping organizations comply with drug regulations through a comprehensive drug development model incorporating augmented Intelligence (A.I.) and data analytics. Our team of industry experts is equipped to help both emerging biotechs and established pharmaceuticals understand how to use A.I. and machine learning to stay on top of rapidly changing regulatory requirements. We're here to help navigate the complex world of compliance more manageable than ever!??Click here for more.



要查看或添加评论,请登录

Edward Narke的更多文章

社区洞察

其他会员也浏览了